Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
2001 1
2002 1
2003 1
2004 1
2005 7
2006 7
2007 10
2008 3
2009 14
2010 13
2011 4
2012 4
2013 7
2014 6
2015 8
2016 2
2017 5
2018 4
2019 5
2020 7
2021 11
2022 5
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.
Yamaki H, Kono M, Wakisaka R, Komatsuda H, Kumai T, Hayashi R, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Hayashi T, Kobayashi H, Katada A. Yamaki H, et al. Among authors: ohkuri t. Cancer Immunol Immunother. 2023 Aug;72(8):2799-2812. doi: 10.1007/s00262-023-03460-0. Epub 2023 May 12. Cancer Immunol Immunother. 2023. PMID: 37173455 Free PMC article.
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy.
Nagato T, Komatsuda H, Hayashi R, Takahara M, Kishibe K, Yasuda S, Yajima Y, Kosaka A, Ohkuri T, Oikawa K, Harabuchi S, Kono M, Yamaki H, Wakisaka R, Hirata-Nozaki Y, Ohara K, Kumai T, Katada A, Hayashi T, Harabuchi Y, Kobayashi H. Nagato T, et al. Among authors: ohkuri t. Cancer Immunol Immunother. 2023 Jul;72(7):2087-2098. doi: 10.1007/s00262-023-03394-7. Epub 2023 Feb 22. Cancer Immunol Immunother. 2023. PMID: 36811663 Free PMC article.
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Kobayashi H, Harabuchi Y. Kono M, et al. Among authors: ohkuri t. Oncoimmunology. 2022 Jan 3;11(1):2021619. doi: 10.1080/2162402X.2021.2021619. eCollection 2022. Oncoimmunology. 2022. PMID: 35003900 Free PMC article.
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
Kono M, Kumai T, Hayashi R, Yamaki H, Komatsuda H, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Kobayashi H, Harabuchi Y. Kono M, et al. Among authors: ohkuri t. Cancer Immunol Immunother. 2021 Dec;70(12):3421-3434. doi: 10.1007/s00262-021-02940-5. Epub 2021 Apr 18. Cancer Immunol Immunother. 2021. PMID: 33866408 Free PMC article.
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer.
Ohara M, Ohara K, Kumai T, Ohkuri T, Nagato T, Hirata-Nozaki Y, Kosaka A, Nagata M, Hayashi R, Harabuchi S, Yajima Y, Oikawa K, Harabuchi Y, Sumi Y, Furukawa H, Kobayashi H. Ohara M, et al. Among authors: ohkuri t. Cancer Immunol Immunother. 2020 Jun;69(6):989-999. doi: 10.1007/s00262-020-02524-9. Epub 2020 Feb 21. Cancer Immunol Immunother. 2020. PMID: 32086539 Free PMC article.
124 results